While the FLOW trial included patients with CKD down to an eGFR of 25 mL/min/1.73 m, it did not specifically focus on individuals already on dialysis
In UK clinical practice, when product-specific validated stability data are unavailable, an assigned beyond-use date (BUD) for a reconstituted preparation must be determined by the licensed aseptic unit or compounding pharmacy responsible for its preparation
A 2022 study published in The New England Journal of Medicine found tirzepatide helped patients lose up to 20.9% of body weight
Unlike prior reports of fasting beyond 21 days in non-obese individuals [11, 12], this case demonstrates substantial weight loss (125 pounds) accompanied by improvements in depression, anemia, hypoxia/hypercapnia, functional status, and left ventricular (LV) mass
Boehringer Ingelheim and Zealand Pharma are presenting full Phase III SYNCHRONIZE-1 data on survodutide, their glucagon/GLP-1 dual agonist: 16.6% average weight loss at 76 weeks versus 3.2% on placebo
Because the two pathways use different intracellular mechanisms, combining them produces additive to synergistic GH release that saturating either receptor alone cannot achieve